Mycobacterium leprae Vaccines
Creative Biolabs is able to provide the state-of-art services for any Mycobacterium leprae vaccines project with qualitative measurements. Our scientists specialized in Mycobacterium leprae vaccines studies will work with you to develop the most appropriate strategy that will offer the most meaningful data for your research. We guarantee the finest results for our customers all over the world.
Mycobacterium leprae, a member of Mycobacteriaceae family, is responsible for a wide variety of human diseases such as leprosy. This disease is characterized by skin, eyes, nose, muscles as well as peripheral nerve trunk damage. Leprosy is also associated with high disabling deformities and infections in warm tropical regions. In addition, Mycobacterium leprae is an intracellular, pleomorphic, acid-fast rod-shaped, pathogenic bacterium. The size of Mycobacterium leprae is similar to Mycobacterium tuberculosis, which is about 1-8 μm in length and 0.2-0.5 μm in diameter. Recent studies show that the infected individuals may exhibit a broad spectrum of clinical and histopathological responses to this bacterium and the mechanisms of transmission are not completely understood but more likely spread through respiratory secretions from person to person.
Fig.1 The Genome-wide Analyse of Mycobacterium leprae. (Schuenemann V.J, et al., 2013)
The BCG Vaccines
The leprosy is regarded as a significant public health challenges, especially in developing countries. This poverty-associated disease requires better methods to improve disease control around the world. The methods usually include infection detection and early diagnosis as well as vaccination. Bacillus Calmette Guerin (BCG) vaccine is a vaccine for tuberculosis, but now it can also be used as a leprosy vaccine owing to the similar pathogenic bacteria. BCG immunotherapy has been used in many leprosy children or young patients from a number of clinical trials and observational studies and the data show that it is safe and efficient for vaccination. However, the results also indicate that the protective effects of this vaccine change from 26% to 61% in adults. BCG vaccine should further improve immunization capacity to TB and leprosy.
The Candidates for Mycobacterium leprae
In order to develop a more effective vaccine for M. leprae, a number of purified recombinant proteins (ML2531, ML2380, ML2055, and ML2028) of M. leprae have been identified in a pre-clinical testing. The data show that they can offer enough protective efficacy. Meanwhile, studies also reveal that it has the possibility of choosing the same potential targets for both TB and leprosy prevention because of the homology of these two bacteria. Two recombinant fusion proteins (ID83/GLA-SE and ID93/GLA-SE) can reduce the inflammation and bacterial growth in mouse models of leprosy. Meanwhile, the studies also indicate Ag85B-ESAT6 is a candidate for leprosy and the data suggest that the overexpression of Ag85B can significantly increase the protective efficacy of BCG against M. leprae. In this condition, a new candidate vaccine platform, based on Ag85B/ESAT6 could be established in the future, which can offer a more effective vaccine for leprosy.
Our Services for Mycobacterium leprae Vaccines
Our platform provides a full range of in vivo and in vitro preclinical studies for M. leprae vaccine development. By focusing on quality, scientific expertise, flexibility, and responsiveness, our scientists and staff are dedicated to providing a flexible and expedient solution to meet global regulatory standards. Experienced teams of researchers and technicians have enabled our company to create an environment to undertake any research to the highest of standards with a knowledge that spans a wide range of M. leprae vaccines development and therapeutic areas.
- Mature vaccine development platform
- Cost-effective and efficient services
- One-stop resolution for vaccine studies
Creative Biolabs is a forward-looking research institute as well as a leading custom service provider in the field of the vaccine development services. We can provide many flexible options, from which you can always find a better match for your particular project. Please feel free to contact us for more information.
Reference
- Schuenemann V.J, et al. (2013). “Genome-wide comparison of medieval and modern Mycobacterium leprae.” Science. 341(6142), 179-83.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
